Cyproheptadine hydrochloride sesquihydrate
SIGMA/C6022 - ≥98% (TLC), solid
Synonym: Piperidine, 4-
CAS Number: 41354-29-4
Empirical Formula (Hill Notation): C21H21N·HCl·1.5H2O
Molecular Weight: 350.88
EC Number: 213-535-1
MDL Number: MFCD00012538
Linear Formula: C21H21N·HCl·1.5H2O
Product Type: Chemical
| assay | ≥98% (TLC) |
| color | white to slightly yellow |
| form | solid |
| InChI | 1S/2C21H21N.2ClH.3H2O/c2* |
| InChI key | ZEAUHIZSRUAMQG-UHFFFAOYSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 200 ![]() |
| SMILES string | Cl.CN1CCC(CC1)=C2/c3cccc |
| solubility | ethanol: soluble |
| methanol: soluble |
| Application: | Cyproheptadine hydrochloride sesquihydrate has been used in: • testing anti-inflammatory activity in serotonin receptor (5-HT) induced inflammation • the inhibition of 5-HT in in vivo and in vitro bioassays in crabs • the inhibition of 5-HT in embryo physiological experiments inhibition of calcitonin gene related peptide (CGRP) |
| Biochem/physiol Actions: | Cyproheptadine hydrochloride sesquihydrate is a serotonin receptor (5-HT2/5-HT1C) antagonist, H1 histamine receptor antagonist and an antipruritic. The inhibition of 5-HT by cyproheptadine improves cognitive function in schizophrenia disorder. Cyproheptadine is effective for treating functional gastrointestinal disorders (FGIDs). Food and Drug Administration (FDA) approved cyproheptadine, has antidepressant and antiplatelet functionality. It may be effective in treating thromboembolic disorders. Cyproheptadine inhibits lysine methyltransferase 7/9 (Set7/9) leading to a decrease in estrogen receptor (ERα) expression and growth arrest in breast cancer cells. |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1 g in poly bottle |
| Packaging: | 100 mg in poly bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H315 - H319 - H335 |
| Precautionary statements | P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Purity | ≥98% (TLC) |
| UNSPSC | 12352200 |


